“Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma”
Purpose: To report the association of pembrolizumab, an immune checkpoint inhibitor (ICI), with giant cell arteritis (GCA) presenting as paracentral acute middle maculopathy (PAMM) secondary to retinal arterial occlusion. Observations: 86-year old male with history of treated choroidal melanoma now...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993620302061 |
| _version_ | 1818921333191344128 |
|---|---|
| author | Ramsudha Narala Sunil A. Reddy Prithvi Mruthyunjaya |
| author_facet | Ramsudha Narala Sunil A. Reddy Prithvi Mruthyunjaya |
| author_sort | Ramsudha Narala |
| collection | DOAJ |
| description | Purpose: To report the association of pembrolizumab, an immune checkpoint inhibitor (ICI), with giant cell arteritis (GCA) presenting as paracentral acute middle maculopathy (PAMM) secondary to retinal arterial occlusion. Observations: 86-year old male with history of treated choroidal melanoma now with metastatic uveal melanoma to the liver on pembrolizumab, an ICI, who presented with acute vision loss in the uninvolved left eye. Spectral domain optical coherence tomography showed band-like increased hyperreflectivity in the middle retinal layers at the level of the inner nuclear layer consistent with PAMM. Intravenous fluorescein angiogram demonstrated significant delay in filling of the superotemporal and inferotemporal arteries with nonperfusion of the temporal retina consistent with multiple branch retinal arterial occlusions. Work-up for GCA was performed and temporal artery biopsy showed healed arteritis. Conclusions and Importance: Pembrolizumab can cause ocular and life-threatening systemic adverse effects and as use of ICIs has increased, it is important to be aware of these associations. There should be a low threshold for GCA work up in patients on ICI therapy who present with acute vision loss and evidence of retinal occlusive disease with or without classic GCA systemic symptoms. |
| first_indexed | 2024-12-20T01:35:59Z |
| format | Article |
| id | doaj.art-24199407f97b43b7b4aec1f1f8ec685d |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-20T01:35:59Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-24199407f97b43b7b4aec1f1f8ec685d2022-12-21T19:58:00ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362020-12-0120100891“Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma”Ramsudha Narala0Sunil A. Reddy1Prithvi Mruthyunjaya2Stanford University Medical Center, Department of Ophthalmology, Palo Alto, CA, USA; Stanford University Medical Center, Department of Medicine, Palo Alto, CA, USAStanford University Medical Center, Department of Ophthalmology, Palo Alto, CA, USA; Stanford University Medical Center, Department of Medicine, Palo Alto, CA, USAStanford University Medical Center, Department of Ophthalmology, Palo Alto, CA, USA; Stanford University Medical Center, Department of Medicine, Palo Alto, CA, USA; Corresponding author. Department of Ophthalmology, Byers Eye Institute, Stanford University Medical Center, 2452 Watson Ct, Palo Alto, CA, 94303, USA.Purpose: To report the association of pembrolizumab, an immune checkpoint inhibitor (ICI), with giant cell arteritis (GCA) presenting as paracentral acute middle maculopathy (PAMM) secondary to retinal arterial occlusion. Observations: 86-year old male with history of treated choroidal melanoma now with metastatic uveal melanoma to the liver on pembrolizumab, an ICI, who presented with acute vision loss in the uninvolved left eye. Spectral domain optical coherence tomography showed band-like increased hyperreflectivity in the middle retinal layers at the level of the inner nuclear layer consistent with PAMM. Intravenous fluorescein angiogram demonstrated significant delay in filling of the superotemporal and inferotemporal arteries with nonperfusion of the temporal retina consistent with multiple branch retinal arterial occlusions. Work-up for GCA was performed and temporal artery biopsy showed healed arteritis. Conclusions and Importance: Pembrolizumab can cause ocular and life-threatening systemic adverse effects and as use of ICIs has increased, it is important to be aware of these associations. There should be a low threshold for GCA work up in patients on ICI therapy who present with acute vision loss and evidence of retinal occlusive disease with or without classic GCA systemic symptoms.http://www.sciencedirect.com/science/article/pii/S2451993620302061PembrolizumabImmune checkpoint inhibitorGiant cell arteritisRetinal arterial occlusionParacentral acute middle maculopathy |
| spellingShingle | Ramsudha Narala Sunil A. Reddy Prithvi Mruthyunjaya “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” American Journal of Ophthalmology Case Reports Pembrolizumab Immune checkpoint inhibitor Giant cell arteritis Retinal arterial occlusion Paracentral acute middle maculopathy |
| title | “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” |
| title_full | “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” |
| title_fullStr | “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” |
| title_full_unstemmed | “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” |
| title_short | “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma” |
| title_sort | giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma |
| topic | Pembrolizumab Immune checkpoint inhibitor Giant cell arteritis Retinal arterial occlusion Paracentral acute middle maculopathy |
| url | http://www.sciencedirect.com/science/article/pii/S2451993620302061 |
| work_keys_str_mv | AT ramsudhanarala giantcellarteritismanifestingasretinalarterialocclusionandparacentralacutemiddlemaculopathyinapatientonpembrolizumabformetastaticuvealmelanoma AT sunilareddy giantcellarteritismanifestingasretinalarterialocclusionandparacentralacutemiddlemaculopathyinapatientonpembrolizumabformetastaticuvealmelanoma AT prithvimruthyunjaya giantcellarteritismanifestingasretinalarterialocclusionandparacentralacutemiddlemaculopathyinapatientonpembrolizumabformetastaticuvealmelanoma |